image
Healthcare - Biotechnology - NASDAQ - US
$ 2.71
-12.3 %
$ 8.14 M
Market Cap
-0.23
P/E
CASH FLOW STATEMENT
-24.1 M OPERATING CASH FLOW
12.80%
-124 K INVESTING CASH FLOW
-85.07%
4.65 M FINANCING CASH FLOW
20321.74%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Moleculin Biotech, Inc.
image
Net Income -29.8 M
Depreciation & Amortization 127 K
Capital Expenditures -124 K
Stock-Based Compensation 1.98 M
Change in Working Capital 1.62 M
Others 3.15 M
Free Cash Flow -24.2 M

Cash Flow

Millions
Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017 Dec-2016 Dec-2015
OPERATING CASH FLOW
Net Income (29.8) (29.0) (15.9) (17.4) (13.2) (11.9) (9.8) (3.9) (0.7)
Depreciation & Amortization 0.1 0.1 0.2 0.2 0.2 68 K 18 K 6.16 K 0
Deferred Income Tax 0 0 (6.7) (2.3) (4.1) 0 (1.4) 0 0
Stock Based Compensation 2.0 2.3 2.4 1.7 1.5 1.1 0.7 0.4 0
Other Operating Activities 1.9 (1.2) 96 K 85 K 0.5 (3.1) 2.6 0.4 2.06 K
Change in Working Capital 1.6 0.2 1.0 41 K (2.1) 1.6 0.5 (0.3) 0.3
Cash From Operations (24.1) (27.6) (19.0) (17.8) (17.2) (12.2) (7.3) (3.8) (0.4)
INVESTING CASH FLOW
Capital Expenditures (0.1) 67 K 19 K (0.4) 52 K (0.4) 28 K 21.5 K 0
Other Items 0 0 0 2 K 1 K 0 0 99.6 K 0
Cash From Investing Activities (0.1) 67 K 19 K (0.4) 51 K (0.4) 28 K (0.1) 0
FINANCING CASH FLOW
Common Stock Repurchased 0 23 0 0 0 0 0 0 0
Total Debt Repaid 0 0 0 0 0 0 0 (0.3) 0.5
Dividends Paid 0 0 0 0 0 0 0 0 0
Other Financing Activities 0.5 23 K 40 K 12 K 1.6 20 K 4.0 61 0
Cash From Financing Activities 4.7 23 K 74.7 22.5 20.9 K 12.0 10.1 8.9 0.5
CHANGE IN CASH
Net Change In Cash (19.6) (27.8) 55.7 4.4 3.6 (0.6) 2.7 5.0 28.1 K
FREE CASH FLOW
Free Cash Flow (24.2) (27.7) (19.0) (18.1) (17.2) (12.6) (7.4) (3.8) (0.4)